Virtual Library
Start Your Search
P. Xing
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 2
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-039 - Patient Characteristics and Treatment Outcome of Advanced Non-Squamous NSCLC with over 6-Month Disease Control from Icotinib (ID 2806)
09:30 - 09:30 | Author(s): P. Xing
- Abstract
Background:
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has an established role in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Icotinib is an EGFR-TKI with non-inferior efficacy but milder toxicities compared with gefitinib. Disease control for over 6 months suggests that the case is not primary resistant to the drug. The present study investigated the patient characteristics and treatment outcome of advanced non-squamous NSCLC with at least 6-month disease control from icotinib.
Methods:
Non-squamous NSCLC patients with disease control after 6-month icotinib treatment were enrolled and retrospectively analyzed. Clinical characteristics were collected from the medical records. Efficacy and outcome data were analyzed.
Results:
A total of 87 patients were enrolled onto this study in which 56 were female, 18 with brain metastasis, and 32 patients harbored known EGFR mutation. For the overall population, 42(48.3%) patients achieved partial response. Response rate were 65.6%（21/32）and 38.2%（21/55）in patients with EGFR mutation and those with unknown mutation status, respectively(P=0.014). Patients with brain metastasis appeared to have lower response rate (26.7% vs 56.9%, p=0.033).The median progression-free survival (PFS) after 6 months’ icotinib treatment was 9.7 months (95% CI 4.1-15.4 months) for the overall population, and 5.0 months (95% CI 0.6-3.9 months) and 12.9 months (95% CI 3.4-6.2 months) for those with and without brain metastasis, respectively. Median progression-free survival in patients with PR or SD showed no statistically significant difference (15.5 months vs 9.3 months, P=0.477).
Conclusion:
The present study provided evidence from a relatively large single institutional study of icotinib in clinical practice. Patients with disease control for over 6 months showed similar clinical features to those with EGFR mutation. Those patients will have prolonged clinical benefits with continuous icotinib therapy after 6 months, regardless of PR or SD. Brain metastasis is a potential unfavorable predictive factor for PFS for those patients
-
+
P3.01-061 - A Prognostic Model for Platinum-Doublet Regimens as Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (ID 1228)
09:30 - 09:30 | Author(s): P. Xing
- Abstract
Background:
Poor prognosis of advanced non-small-cell lung cancer (NSCLC) patients and the promising therapeutic effect of platinum urge the oncologists to evaluate the role of platinum-doublet as second-line chemotherapy and establish the definition of platinum sensitivity in NSCLC.
Methods:
We retrospectively analyzed 364 advanced NSCLC patients who received platinum-doublet regimens as second-line chemotherapy after platinum-based first-line treatment. Patients were divided into four groups by their time-to-progression (TTP) after first-line chemotherapy: 0-3, 4-6, 7-12, and >12months group, respectively. Treatment efficacy of patients’ overall survival (OS), progression-free survival (PFS) and response rate (RR), as well as treatment-related toxicity, were compared among the four groups. A prognosis score system was established by Cox proportional hazard model.
Results:
All patients had Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. As part of the platinum-doublet regimen,145(39.8%) patients received taxol, 81(22.3%) received gemcitabine, 99(27.2%) received pemetrexed, 32(8.8%) received vinorelbine, 4(1.1%) received etoposide, and 3(0.8%) received irinotecan. The most frequent grade 3/4 toxicity was neutropenia (20.1%) and nausea/vomiting (3.3%).The median follow-up time was 11.0 months. Patients with TTP> 12 months had significant longer survival than the rest of the group after second-line platinum-rechallenge (HR, 0.809; 95% CI: 0.703-0.931;P=0.003).Prognostic score (TAF score) was calculated by adding 1 point each for any of the following: TTP>12 months, age≤60 years, and female, all of which were independent prognostic factors for patient survival (P=0.015, P=0.002, P=0.012, respectively). Median OS were equal to 25.0, 16.0 and 11.0 months for best (2-3 points), intermediate (1 point) and worst (0 point) category, respectively (P<0.0001, Figure 1). Figure 1 Kaplan–Meier curves of overall survival according to patients’ TAF Score. After second-line platinum-based chemotherapy, patients with a TAF Score of 2-3 had significant better survival than those scored 0 or 1 (P<0.0001). Figure 1
Conclusion:
A TAF score of 2 or 3 points indicates a good prognosis if advanced NSCLC patients received platinum-rechallenge after disease progression.
